Newron Pharmaceuticals S.p.A. (0QOI.L)

CHF 7.54

(6.95%)

Operating Expenses Summary of Newron Pharmaceuticals S.p.A.

  • Newron Pharmaceuticals S.p.A.'s latest annual operating expenses in 2023 was 20.68 Million EUR , up 5.14% from previous year.
  • Newron Pharmaceuticals S.p.A.'s latest quarterly operating expenses in 2024 Q2 was 11.09 Million EUR , down 0.0% from previous quarter.
  • Newron Pharmaceuticals S.p.A. reported a annual operating expenses of 19.67 Million EUR in annual operating expenses 2022, up 10.65% from previous year.
  • Newron Pharmaceuticals S.p.A. reported a annual operating expenses of 17.78 Million EUR in annual operating expenses 2021, down -21.66% from previous year.
  • Newron Pharmaceuticals S.p.A. reported a quarterly operating expenses of 10.44 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Newron Pharmaceuticals S.p.A. reported a quarterly operating expenses of 20.68 Million EUR for 2023 FY, up 5.14% from previous quarter.

Annual Operating Expenses Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Operating Expenses of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year Operating Expenses Operating Expenses Growth
2023 20.68 Million EUR 5.14%
2022 19.67 Million EUR 10.65%
2021 17.78 Million EUR -21.66%
2020 22.69 Million EUR -15.37%
2019 26.81 Million EUR 40.27%
2018 19.12 Million EUR 1.44%
2017 18.84 Million EUR -14.47%
2016 22.03 Million EUR -19.83%
2015 27.48 Million EUR 121.89%
2014 12.38 Million EUR 9.47%
2013 11.31 Million EUR -2.63%
2012 11.62 Million EUR 71.86%
2011 6.76 Million EUR -69.87%
2010 22.44 Million EUR -17.17%
2009 27.09 Million EUR 21.78%
2008 22.25 Million EUR 25.19%
2007 17.77 Million EUR -0.94%
2006 17.94 Million EUR 19.02%
2005 15.07 Million EUR 0.0%

Peer Operating Expenses Comparison of Newron Pharmaceuticals S.p.A.

Name Operating Expenses Operating Expenses Difference
Relief Therapeutics Holding AG 114.94 Million CHF 82.003%
Tecan Group AG 254.49 Million CHF 91.872%
Santhera Pharmaceuticals Holding AG 31.33 Million CHF 33.984%
Basilea Pharmaceutica AG 111.63 Million CHF 81.47%
Bachem Holding AG 47.58 Million CHF 56.526%
Siegfried Holding AG 148.34 Million CHF 86.055%
Molecular Partners AG 20.3 Million CHF -1.891%